People

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. FY25 figures use the 2025-03-31 rate (1 INR = 0.0117 USD); market-cap/current holdings use the 2026-05-20 rate (1 INR = 0.01036 USD). Ratios, margins, and multiples are unitless and unchanged.

The People Running This Company

Governance grade: C. Onyx Biotec is a tightly-held Jain family pharma SME — promoter control is 65.1%, zero pledged — but the post-IPO board carries the hallmarks of cosmetic compliance: three independent directors all appointed in the four months before listing, the CFO/CEO sits on the audit committee, and the managing director doubled his own (and his three colleagues') pay by 100% in the IPO year. Skin in the game is real; check-and-balance is light.

1. The People Running This Company

The executive bench is four men paid identically, with two long-tenured founder-promoters at the centre and a recently-added CEO/CFO who is also a promoter. Capability is concentrated in two people who have run this plant since 2008; succession beyond them looks thin.

Why this matters. Sanjay Jain and Naresh Kumar built the business; they own 45% of the company between them and have nowhere else to be. But the bench below them is the worry: Harsh Mahajan wears three hats (CEO, CFO, WTD) at 38, and Lakshya Jain — the only person under 60 with operating depth — is the MD's family member with eight years total experience and no personal stake yet. The "succession plan" is biological.

2. What They Get Paid

Pay is small in absolute terms — $140,400 in aggregate across four executive directors — but every promoter director got a 100% raise in the IPO year while the median employee got 23%. That ratio (executive 100% / staff 23%) is the disclosure to read twice.

Is it earned? On absolute size: yes. $35,100/year for an MD running a $7.5M-revenue pharma plant is below India market for the role. On timing: less defensible. The 100% hike was approved in the same window the company was preparing the RHP — the AR notes new appointments dated May 2024 and increases effective FY25. Pay doubled before public shareholders could vote on it. And the company posted ROCE of just 1.14% and ROE of -0.38% in the reported year (per Screener), so the doubling preceded any operating evidence to justify it.

3. Are They Aligned?

Ownership alignment is genuinely strong. Three promoter individuals hold the entire 65.10% block and not a single share is pledged. There has been zero promoter selling in the four quarters since listing. The smart money flowed out — FIIs unwound from 8.72% to 1.07% — but that was IPO allotment churn, not promoter behavior.

Related-party behavior. Per the RHP, promoter family members have historically drawn salaries from the company outside of director pay — Meenu Jain (Sanjay's spouse), Anita Mahajan (Harsh's spouse), and Mehak Sood Walia at $12,000–35,000/year ranges (FY22-FY24 rates). In FY24 (pre-IPO), the company also carried ~$0.18M of unsecured loans from Sanjay Jain, Naresh Kumar and Harsh Mahajan personally. None of this is unusual for a closely-held Indian SME, and the FY25 AR confirms no related-party transaction exceeded 10% of turnover. But the boundary between family and company finances is porous — the AR's own related-party note lists "gifts" passed between Anita Mahajan, Meenu Jain, Sanjay Jain and Naresh Kumar of ~$12,000 apiece, and salary-payable balances to nine family members at FY24 year-end.

Capital allocation behavior. IPO raised $3.52M (at FY25 rate), of which $1.44M (41%) went to repaying promoter and bank loans rather than growth. No dividend yet (company says "to augment working capital"). Authorised capital was hiked from $1.68M to $2.40M in FY25, leaving headroom for further dilution. No buyback. No ESOP plan disclosed.

Skin-in-the-game score: 7/10. Owners genuinely own the business (top three promoters hold 65%, zero pledge, locked-in cohort still 31% of equity until 2027). They bleed when the stock bleeds — and the stock is down 47.5% from its IPO issue price of $0.71. Three points withheld for: the IPO-year pay doubling, the related-party salary roster for family members, and the use of public capital partly to retire promoter loans.

4. Board Quality

Eight directors. Three independent. The five non-independent seats are all held by promoters (four executive + Parmjeet Kaur as the non-executive woman director, who is also a promoter). Onyx is on the NSE EMERGE SME platform, which exempts it from most of SEBI LODR's tougher board-independence rules — and the board structure reflects that exemption rather than rising above it.

The structural problems.

Harsh Mahajan is CFO, CEO, a Whole-Time Director, and a member of the Audit Committee. That is the single biggest specific governance defect in the filing. The Audit Committee's job is to scrutinise the CFO's numbers. Having the CFO sit on the committee that audits him collapses the check.

All three independent directors joined in July 2024 — four months before listing. They have no operating history with the company. Their independence is "formal" (meets Section 149(6) criteria, signed declarations) but not "real" (no track record of pushing back).

No independent woman director. Parmjeet Kaur is the woman director on the board, but she is also a promoter. The SME exemption permits this, but it means the board has no independent woman's voice and the gender diversity disclosure is technically met without substantively meeting it.

Concentrated chair load. Nitesh Garg chairs both the NRC and the Stakeholders Relationship Committee. Vineet Singh chairs the Audit Committee. Two of the three IDs are doing all the committee work — fine for a small board, but a lot of weight on people in their first listed-board role.

Board Skills Matrix — 0=none, 1=basic, 2=working, 3=deep.

Missing expertise. No board member has a public-markets or investor-relations track record. No board member has pharma-regulatory deep expertise (USFDA, EU-GMP) despite the company's stated overseas-export ambition. No audit-firm partner, no PSU/banking professional, no listed-board veteran among the IDs.

What works. Zero litigation — against the company, the directors, or the promoters. Statutory auditor (R C A and Co LLP) issued an unqualified report. Whistleblower policy in place. Independent directors held one meeting without management on 29-03-2025 (the minimum required). All 10 board meetings during FY25 had full attendance from the two MDs being re-appointed. The mechanical compliance is clean.

5. The Verdict

Governance grade: C.

What works (strongest positives):

Owners eat their own cooking. 65.10% promoter holding, zero pledged, zero promoter selling through a 47% price drawdown. Three named promoter individuals hold the entire promoter block — no opaque trust structures, no offshore vehicles.

Disclosure hygiene is clean. No qualified audit opinion, no SEBI/regulatory actions, no litigation against directors or promoters, no material RPT above the 10%-of-turnover threshold. The mechanical filings are in order.

Operators, not raiders. Sanjay Jain and Naresh Kumar have run this single business in this single building since 2008. There are no other listed-company directorships, no group holdings, no sister concerns visibly being subsidised.

Real concerns:

CFO on the Audit Committee. Harsh Mahajan is CFO, CEO, a Whole-Time Director, and sits on the committee that should audit him. Fixable with one resignation, but currently a structural failure.

100% pay hike in the IPO year. All four executive directors saw managerial remuneration double in the year the company listed. Median employees got 23%. No performance-linked component is disclosed.

Cosmetic independence. All three independent directors were appointed in July 2024, just before listing. None has a public-markets track record. Their committee work is the only governance check on a board that is 5/8 promoter.

Family salary roster. Per the RHP, four named promoter spouses/relatives drew salaries from the company in the years leading to IPO. The FY25 AR says no RPT exceeded 10% of turnover, but the boundary remains porous.

What would change the grade:

Upgrade to B if: Harsh Mahajan steps off the Audit Committee, an independent pharma-regulatory voice joins the board, and FY26 pay decisions show restraint after the IPO-year jump.

Downgrade to D if: promoter pledging appears, a material related-party transaction is approved without independent-director scrutiny, the second-anniversary lock-in (Nov-2027) is followed by promoter selling into a weak stock, or the IPO-proceeds utilisation deviates from the RHP plan.

The watch item. Onyx sits at the intersection of two real risks — operating returns have collapsed (ROCE 1.14%, ROE negative in TTM per Screener) while management just doubled its pay. Outside shareholders are paying for an IPO-year pay reset now disconnected from performance. That is what to track in FY26 AR disclosures.